Research Study

A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
Principal Investigator 
Mark FitzGerald

Overview

Body Locations and Systems 
Asthma
ClinicalTrials.gov# 
NCT02821416
Status 
Recruiting
Study Start/End 
Oct 12, 2016 to Dec 28, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Linda Hui, Research Coordinator
Phone 
604-875-5698
Purpose of Study 

This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.